Trupanion, Inc. — Form 10-Q Summary
Business context and reporting period
Trupanion provides medical insurance for cats and dogs in the United States, Canada, Europe, Puerto Rico and Australia. The filing covers the quarter and nine months ended September 30, 2022, compared with the corresponding 2021 periods. The company operates through subscription and other business segments.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Revenue | $233.8 million | $181.7 million | $659.2 million | $504.6 million |
| Revenue growth | 29% | 31% | ||
| Operating loss | $(11.9) million | $(7.2) million | $(33.8) million | $(29.4) million |
| Net loss | $(12.9) million | $(6.8) million | $(35.4) million | $(28.5) million |
| Net loss per share | $(0.32) | $(0.17) | $(0.87) | $(0.71) |
| Operating cash flow | $(9.0) million | $2.3 million | ||
| Cash, cash equivalents and restricted cash | $99.0 million | $116.0 million |
Gross margin declined to approximately 13% in Q3 2022 from 16% in Q3 2021, and to approximately 13% for the nine months from 15% in the prior-year period. Operating margin was approximately negative 5.1% in Q3 2022 versus negative 4.0% in Q3 2021, and negative 5.1% for the nine months versus negative 5.8%. Net margin was approximately negative 5.5% in Q3 2022 versus negative 3.8% in Q3 2021, and negative 5.4% for the nine months versus negative 5.6%.
- Subscription revenue increased 20% in Q3 and 21% for the nine months, primarily from a 19% increase in subscription pets enrolled.
- Other business revenue increased 49% in Q3 and 54% for the nine months, driven primarily by a 48% increase in enrolled pets in that segment.
- Total pets enrolled reached 1,439,605, up 30% year over year; subscription pets enrolled reached 808,077, up 19%.
- Monthly average revenue per subscription pet was $63.80 in Q3 and $64.09 for the nine months. Average monthly retention was 98.71%, essentially unchanged from 98.72%.
- Average pet acquisition cost was $268 in Q3, down from $280, but $291 for the nine months, up from $281.
- Veterinary invoice expense increased 37% in Q3 and 34% for the nine months, reflecting growth in enrollment and higher veterinary care cost and utilization.
- New pet acquisition expense increased 14% to $22.4 million in Q3 and to $67.0 million for the nine months.
- Stock-based compensation was $8.6 million in Q3 and $24.8 million for the nine months, compared with $6.4 million and $21.4 million, respectively, in the prior-year periods.
Liquidity, debt and capital resources
At September 30, 2022, cash and cash equivalents were $85.5 million, short-term investments were $97.4 million and long-term investments were $55.1 million. Management reported $182.9 million of cash, cash equivalents and short-term investments and $90.0 million of remaining credit-facility availability.
- Net cash used in operating activities was $9.0 million for the nine months, compared with $2.3 million provided in 2021. Management attributed the decline primarily to higher acquisition spending and faster payment of veterinary invoices.
- Net cash used in investing activities was $37.0 million, including $11.6 million of property and equipment purchases and $2.8 million for the Smart Paws acquisition.
- Financing activities provided $46.1 million, principally from the new term loan, partly offset by $5.8 million of share repurchases.
- Outstanding debt was $59.7 million, including $53.6 million classified as long-term debt. The credit facility bears interest at a floating rate; the rate was approximately 7.20% at September 30, 2022.
- The credit facility provides up to $150.0 million, is secured by substantially all company assets and includes financial and other covenants. The company was in compliance with all covenants at quarter-end.
Material changes, outlook and unusual items
- Profitability weakened year over year in the quarter as veterinary invoice expense grew faster than revenue and technology, development and administrative spending increased.
- Technology and development expense increased 49% for both the quarter and nine months, including investment in pre-revenue products and international expansion.
- The company acquired Smart Paws GmbH, a pet insurer operating in Germany and Switzerland, on August 31, 2022, for approximately $2.8 million in net cash. The acquisition was immaterial to consolidated results and generated $0.2 million of acquisition-related costs.
- Foreign currency translation losses were $3.9 million in Q3 and $8.2 million for the nine months; unrealized losses on available-for-sale securities were $0.9 million for both the quarter and nine months.
- On October 14, 2022, the company signed an agreement to acquire Royal Blue s.r.o., the parent of PetExpert, with closing expected in the fourth quarter of 2022. The filing does not provide a purchase price.
- Management stated that available liquidity and borrowings were sufficient to fund operations and regulatory capital requirements for the next 12 months, while noting that additional financing may be pursued as the company grows or undertakes strategic opportunities.
- No specific revenue, earnings or cash-flow guidance is provided in the filing text. Forward-looking statements remain subject to substantial risks and uncertainties.
Principal risks and contingencies
- The company has incurred significant cumulative losses and may not achieve or maintain profitability.
- Veterinary invoice reserves rely on actuarial estimates and could be materially understated if claim frequency, utilization or veterinary costs increase.
- Insurance subsidiaries must maintain regulatory capital, restricting the use of certain assets and potentially increasing future capital requirements.
- Growth depends on member acquisition, retention, veterinary referral channels and the effectiveness of marketing investments. Other business relationships may be terminated and generally have lower margins.
- The business is exposed to competition, inflation and economic downturns, foreign-exchange movements, regulatory approvals, cybersecurity and technology failures, litigation and debt-covenant compliance.
- The company disclosed no material legal proceedings at the reporting date, although ordinary-course claims and regulatory matters could become material.
Important facts for investors to verify
- Whether revenue growth can continue without further deterioration in veterinary invoice margins.
- Whether higher veterinary costs and utilization are reflected adequately in pricing and reserves.
- The trajectory of operating cash flow and the company’s ability to fund growth while servicing floating-rate debt.
- Regulatory capital availability within insurance subsidiaries and restrictions on transferring cash to the parent.
- The financial terms, funding requirements and integration risks associated with the PetExpert transaction and international expansion.
- Whether subscription retention remains near 98.7% and whether pet acquisition cost supports the company’s targeted return assumptions.
- The effect of stock-based compensation, share repurchases and future financing on shareholder dilution and liquidity.